http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104961804-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate | 2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104961804-B |
| titleOfInvention | P 38 alpha antagonistic peptide mutant and its application |
| abstract | The invention discloses the application of p 38 alpha antagonistic peptide PT5 mutant, i.e. p 38 alpha antagonistic peptide PT5 mutant can be used for the medicine for preparing treatment myocardial ischemia-reperfusion injury.The present invention is stronger compared with PT5 for TAB1 and rejection ability that p 38 alpha interacts through GST pull experiments and Kinase assay experiment proofs PT5 mutant PT5 2, therefore caused by TAB1/p38 α interactions can be applied among the treatment of myocardial ischemia-reperfusion injury, a kind of new drug candidate is provided for the research and development of clinically medicament for myocardial ischemia-reperfusion injury. |
| priorityDate | 2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 107.